Core Viewpoint - AI is significantly transforming the productivity of the healthcare industry, with a focus on enhancing diagnostic efficiency and accuracy in medical institutions [1][2]. Group 1: AI in Healthcare - The Chinese government is promoting the "Artificial Intelligence +" initiative to better integrate digital technology with manufacturing and market advantages [2]. - At the recent China International Medical Equipment Fair (CMEF), AI was a prominent topic, with nearly 5,000 companies showcasing advanced AI medical products and services [2]. - The Vice President of KAILI Medical emphasized the importance of AI in primary healthcare, aiming to shift the market focus from hospitals to home healthcare [2]. Group 2: Market Position and Growth - KAILI Medical is a leading domestic medical device company, ranking fourth in the domestic ultrasound imaging diagnostic equipment market and first among domestic brands in digestive endoscopy [4]. - The medical device industry has experienced fluctuations due to centralized procurement and reduced hospital bidding demands, but the market is recovering due to large-scale equipment updates [4][5]. - The government has initiated policies to support equipment updates, with funding distributed based on a 9:1 principle between central and local governments [4]. Group 3: Impact of Centralized Procurement - Centralized procurement has led to a decrease in equipment sales prices; however, the increase in supply volume has positively impacted overall sales and market share for KAILI Medical [5]. - The company believes that success in centralized procurement relies on comprehensive strength and product competitiveness rather than just low prices [5]. Group 4: AI Product Development - KAILI Medical has been investing in AI technology since 2016, launching the world's first AI technology for automatic image capture in 2018, enhancing product performance [6]. - The company’s AI applications in the fields of obstetrics and gastroenterology have received positive feedback, with AI diagnostic accuracy exceeding 95% in radiology [6]. - The company is focusing on expanding AI clinical applications to assist doctors in various diagnostic scenarios [6]. Group 5: International Market Strategy - The impact of the recent "reciprocal tariffs" imposed by the U.S. is minimal for KAILI Medical, as U.S. market revenue constitutes less than 2% of total revenue [7]. - The company has established a solid overseas presence and plans to increase investments in international markets, particularly in Europe, Russia, India, and Latin America [8].

智通财经4月9日电，记者从开立医疗方面获悉，美国加征"对等关税"对公司影响不大，因为美国市场收 入在公司营业收入中的占比不到2%，且美国代理商已提前进行了适当备货。公司在海外布局多年、运 营较完善，近年来加强本地化建设，逐步在海外建立分公司。未来，公司会进一步加大海外市场投入， 重点在欧洲、俄罗斯、印度、拉美等地区拓展布局。（智通财经记者 何凡） 开立医疗回应美关税调整：公司美国市场收入占比不到2% ...

Group 1 - The 91st China International Medical Equipment Fair (CMEF) opened on April 8, showcasing Shenzhen Kaili Biomedical Technology Co., Ltd.'s (Kaili Medical) AI specialty solutions and core devices, highlighting its forward-looking layout and strong independent innovation in the smart medical field [2] - Kaili Medical launched comprehensive solutions covering ultrasound medical imaging, endoscopic diagnosis and treatment, minimally invasive surgery, and cardiovascular intervention, empowering precise smart healthcare [2] - The exhibition featured high-end ultrasound devices such as the full-body and obstetric ultrasound HETU® S80 and Dream Stream P80, equipped with the new C-Field+ intelligent platform for more accurate imaging [2] Group 2 - In the field of cardiovascular intervention, Kaili Medical's V-reader® intravascular ultrasound diagnostic system and SonoSound® catheter form an intelligent ultra-wideband intravascular imaging solution, enhancing the efficiency and usability for physicians [3] - The integration of AI and advanced technologies in the medical industry is expected to provide more opportunities for future development, with Kaili Medical focusing on the "medical devices + AI" strategy to create intelligent solutions across various medical scenarios [3]

Core Viewpoint - The 91st China International Medical Equipment Fair (CMEF) showcased cutting-edge medical technologies and devices from nearly 5,000 global enterprises, emphasizing the theme of "Innovative Technology, Leading the Future" [1] Company Highlights - KaiLi Medical, a leading domestic enterprise in ultrasound medical imaging and endoscopy, presented its innovative products and solutions under the theme "Intelligent Wave, Surge Towards New" at CMEF, highlighting its comprehensive smart diagnosis and treatment ecosystem [3] - The company introduced several high-end products across four major product lines: ultrasound medical imaging, endoscopic diagnosis and treatment, minimally invasive surgery, and cardiovascular intervention, demonstrating its strong self-research capabilities [4] - In the ultrasound medical imaging sector, KaiLi Medical showcased its ultra-high-end full-body ultrasound product, HeTu® S80, and the intelligent obstetric ultrasound product, MengXi TMP80, both featuring advanced imaging technologies for enhanced clinical solutions [4] - The new generation of the iEndo smart endoscope platform was launched, utilizing a multi-core heterogeneous hardware architecture and advanced imaging technologies to improve early cancer screening and complex lesion diagnosis [6] - In minimally invasive surgery, the company presented the "LingZhu" 4K 3D fluorescence imaging platform, which integrates various imaging modalities for precise diagnosis and treatment [7] - The cardiovascular intervention segment featured the V-reader® series intravascular ultrasound diagnostic system, designed for flexible use in sterile environments, enhancing access to quality medical resources [8] R&D and Innovation - KaiLi Medical has significantly increased its R&D investment, with expenditures reaching 338 million yuan, a year-on-year increase of 28.33%, surpassing the total R&D expenses of 2022 [10] - The company has been at the forefront of AI applications in the medical field, having launched the world's first AI technology for automatic image capture in 2018, and recently achieved a significant milestone with the first domestic AI medical device for prenatal ultrasound [10] - The introduction of the 5G + AI cloud imaging platform at CMEF allows regional hospitals to utilize AI services across various ultrasound devices, addressing interoperability issues within medical networks [11] Strategic Vision - KaiLi Medical adheres to the philosophy of "Creating More Possibilities for Life," focusing on a multi-product line strategy and continuous investment in high-end product development, aiming to fill gaps in the domestic market and enhance its competitive advantage [15]

报名：首届全球眼科大会 | 议程更新 那么，本次 医学影像展区 都将展出哪些创新产品呢？一起来看看吧！ # GE医疗 展位 ：3R13 展品 ： "英雄"磁共振结合"Sonic深度学习平台" GE医疗 是一家全球领先的医疗科技、诊断药物和数字化解决方案的创新企业，致力于通过整合解决方案和服 务提升医疗效率和精准度。公司业务遍及 160多个国家和地区 ，年营收超196亿美元，拥有全球员工51,000 名。 GE医疗的 SIGNA Hero磁共振设备通过搭载人工智能深度学习Sonic平台 ，实现了"脑心同治"理念的落地。该 设备将传统超过一小时的检查时间缩短至半小时，仅需一次造影剂注射即可完成脑心联合评估，大幅提升检查 效率和成功率。此外，SIGNA Hero还具备 高分辨斑块成像功能 ，能够评估缺血性脑卒中和心脏病风险，为不 明原因卒中患者提供全面诊断信息。 基于SIGNA Hero的脑心同治及肿瘤精准诊疗应用方案已入选《2024年高端医疗装备推广应用项目》，并由天 津医科大学总医院牵头，联合多家医院进行临床应用研究。 # 飞利浦医疗 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 ...

Core Views - The report maintains a positive outlook on the biopharmaceutical industry, expecting it to outperform the market due to minimal impact from recent U.S. tariff policies on drug sectors [4][5] - The report emphasizes continued optimism for innovative drugs and sectors related to consumer recovery, highlighting the resilience of the pharmaceutical sector amidst tariff changes [4][5] Industry Insights - The recent U.S. tariff policy has a limited effect on the pharmaceutical sector, with most drugs, including various chemical drugs, vaccines, and biological products, exempt from tariffs. Raw materials like vitamins and amino acids are also on the exemption list [4][27] - The report suggests that the innovative drug sector has shown significant growth, providing a selection of quality stocks based on criteria such as strong fundamentals, potential in research pipelines, and favorable cash positions [4][5] Investment Strategy - The report recommends focusing on four main themes: "Innovation," "Going Global," "Equipment Upgrades," and "Consumer Recovery" [5] - **Innovation**: Invest in globally competitive innovative drugs and promising categories, with specific companies highlighted such as BeiGene and East China Pharmaceutical [5] - **Going Global**: Identify opportunities in overseas markets, with companies like Mindray Medical and Sinocare suggested for investment [5] - **Equipment Upgrades**: Expect support for medical equipment updates from government policies, with companies like Mindray Medical and United Imaging Healthcare recommended [5] - **Consumer Recovery**: Anticipate a rebound in sectors like ophthalmology and aesthetic medicine, with companies like Prue Eye Hospital and Tongce Medical highlighted [5] Key Companies to Watch - **Nocare Biopharma**: Expected to achieve revenue of 1.009 billion in 2024, with a 49% year-on-year growth in sales of its core product, Oubatinib [6] - **Sihuan Pharmaceutical**: Strong fundamentals with a stable performance, and a promising pipeline with multiple products expected to be approved between 2025 and 2027 [9] - **East China Pharmaceutical**: Anticipated growth driven by the commercialization of domestic nuclear medicine products and a robust R&D pipeline [10] - **China Biopharmaceutical**: Rapid revenue growth with an increasing proportion of innovative products, indicating potential for accelerated profit growth [11] - **Aier Eye Hospital**: Benefiting from growing demand in ophthalmology and favorable policies for private specialty hospitals, with significant expansion plans [21]

Investment Rating - The report does not explicitly state an investment rating for the high-end medical device industry Core Insights - The high-end medical device market is experiencing stable growth, with a global market size of $345.4 billion in 2023, reflecting a year-on-year increase of 6.64% [2] - In China, the high-end medical device market reached ¥414.45 billion in 2023, growing by 24.9% year-on-year, with a CAGR of 27.8% from 2015 to 2023 [4] - The report highlights the importance of technological innovation and domestic production capabilities in reducing reliance on imports and enhancing market competitiveness [11][14] Summary by Sections High-End Medical Devices - High-end medical devices are characterized by high technical content, significant R&D investment, and complex manufacturing processes, playing a crucial role in precision diagnosis and treatment [1] - The global high-end medical equipment market is primarily concentrated in the US, Europe, and China, which together account for approximately 86% of the market share in 2023 [2] Market Growth and Segmentation - The treatment equipment segment holds the largest market share at 28.67%, followed closely by diagnostic testing equipment at 27.91% in the global market [2] - In China, treatment equipment also leads with a 27.47% market share, followed by diagnostic testing equipment at 26.56% [4] Domestic Innovation and Policy Support - The Chinese government has been actively promoting the development of high-end medical devices to reduce dependence on imports, with a significant increase in the number of approved innovative medical devices [11] - In 2024, the National Medical Products Administration approved 65 innovative medical devices, marking a 6.6% increase from the previous year [12] R&D Investment and Technological Advancements - R&D investment in the high-end medical device sector has been increasing, with companies like Mindray Medical and MicroPort Medical leading in R&D spending [19] - The report notes that the cost structure of high-end medical devices is heavily concentrated on core components and R&D, with core components accounting for 40%-60% of total costs [23] Market Dynamics and Internationalization - The report indicates that the high-end medical device industry is undergoing a transformation driven by domestic substitution and international expansion, with Chinese companies increasingly entering global markets [29][30] - In 2023, China's high-end medical device exports grew by 28%, with significant contributions from imaging equipment [30] Future Trends - The aging population is driving demand for chronic disease management and home medical devices, pushing the industry towards smart and precise development [36] - The integration of AI and robotics in high-end medical devices is expected to enhance diagnostic efficiency and patient outcomes, reshaping traditional healthcare delivery models [38]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [3] Core Viewpoints - The chemical pharmaceutical sector has shown the highest growth among sub-sectors, driven by expectations around "centralized procurement optimization discussions" and the "Class B medical insurance catalog" [8] - The trade war environment is expected to enhance the market share of domestic blood products and high-end medical devices due to increased costs of foreign imports [8] - The report suggests a cautious approach for April, focusing on specific segments that may benefit from the trade war, such as domestic blood products and high-end medical devices [8] Summary by Sections Industry Weekly Viewpoints - The pharmaceutical and biotechnology sector's weekly return was 1.20%, outperforming the CSI 300 by 2.57%, ranking 3rd among 31 primary sub-indices [7] - The chemical pharmaceutical sub-sector had the highest weekly growth of 3.45%, while the medical services sector saw the largest decline of 2.12% [7][8] Industry Performance and Valuation - The pharmaceutical and biotechnology sector's recent one-month return was 2.94%, with a relative return of 3.63% against the CSI 300, ranking 10th among 31 primary sub-indices [9][18] - The current PE (TTM) for the pharmaceutical and biotechnology sector is 26.88 times, which is below the historical average of 30.99 times [14][15] Market Tracking - The chemical pharmaceutical sector has shown the largest growth over the past year, with a 16.51% increase, while the biological products sector has seen a decline of 11.36% [24][25] - The report highlights the potential for price increases in blood products due to supply and demand changes, particularly for domestic manufacturers [8] Focus on Individual Stocks - The report recommends focusing on specific companies in the blood products and high-end medical device sectors, such as Palin Bio, Tian Tan Bio, and Mindray Medical [8] - In the consumer healthcare sector, companies like Aier Eye Hospital and Yifeng Pharmacy are highlighted as potential beneficiaries of government stimulus policies [8] Industry and Company Dynamics - Recent policy developments include the approval of new medical service pricing for brain-computer interface technologies, indicating a growing focus on innovative medical solutions [40] - The report notes significant recent approvals for various pharmaceutical products, including those from companies like Jingxin Pharmaceutical and Antu Bio [41]

报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 2025年4月8日至11日， 第91届中国国际医疗器械（春季）博览会（CMEF） 将在上海国家会展中心拉开帷幕。作为亚太地区规模最大的医疗科技展会，CMEF始终 是行业风向标，不仅汇聚全球创新技术，更见证着产业发展的新趋势。本届展会预计吸引 全球30多个国家和地区的近 5000家 企业，携 数万款 前沿产品集中亮相 ，以"创新科技，智领未来"为主题，共同探讨医疗科技的突破与未来。 CMEF不仅是一场产品与技术的集中展示，更是医疗行业生态的一次深度联动。从人工智能驱动的医学影像，到手术机器人赋能精准医疗，从智慧医院建设，到国 产医疗设备的崛起，CMEF2025通过高规格论坛、产业对话和技术展示，构建起全方位的交流平台，为行业发展提供新的思路与动能。 在这一医疗科技的年度盛会上，哪些企业将携最新技术亮相？哪些创新产品值得重点关注？ 思宇梳理了本届CMEF的亮点企业，一起来看它们如何在这场科技盛宴 中抢占先机！ P.S. 展位图附于文末，感兴趣的读者可按图索骥 ...

Group 1: Key Recommendations - The report highlights Vanadium Titanium Co., Ltd. (000629) as a key recommendation, indicating that high-end production capacity is being gradually released, suggesting an impending profit turning point [8] - The report notes that the company achieved a revenue of 13.209 billion yuan in 2024, a year-on-year decrease of 8.1%, and a net profit attributable to shareholders of 285 million yuan, down 73.0% year-on-year [8][9] - The report emphasizes the structural changes in downstream demand, with an increase in vanadium demand in non-steel applications, particularly in energy storage [9] Group 2: Industry Insights - The vanadium market is currently experiencing an oversupply, with the average market price of vanadium pentoxide in 2024 at approximately 80,500 yuan per ton, a year-on-year decrease of 25.9% [9] - The titanium dioxide market is also facing oversupply due to weak demand in downstream sectors such as real estate and coatings, with the company’s titanium dioxide revenue in 2024 reaching 3.517 billion yuan, a year-on-year increase of 2.5% [10] - The report forecasts that the company plans to produce 52,500 tons of vanadium products and 22,550 tons of sulfuric acid titanium dioxide in 2025, indicating a focus on expanding production capacity [11] Group 3: Market Performance - The pharmaceutical and biotechnology sector saw an overall increase of 0.98% in the last week, outperforming the CSI 300 index by 0.97 percentage points [12] - The report indicates that the PE valuation for the pharmaceutical and biotechnology sector is currently at 27.11 times, which is at a historically low level [12] - The report suggests that the recent performance of innovative drugs has been strong, with several companies reporting excellent earnings data [14]